Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Schöffski P, Sanfilippo R, Martín-Broto J, Kawai A, Desai J, LoRusso P, Maki RG, Jones RL, Blay JY, Smrke A, Abdul Razak A, Italiano A, Sebio A, Bahleda R, Lee YC, van der Graaf WTA, Zhang X, Biyukov T, Teufel M, Fu E, Lahmar M, Wagner AJ

Open source

DOI: 10.1158/1078-0432.ccr-26-0509
Published: 2026 Jun 10
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0509,
  title = {Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.},
  author = {Schöffski P and Sanfilippo R and Martín-Broto J and Kawai A and Desai J and LoRusso P and Maki RG and Jones RL and Blay JY and Smrke A and Abdul Razak A and Italiano A and Sebio A and Bahleda R and Lee YC and van der Graaf WTA and Zhang X and Biyukov T and Teufel M and Fu E and Lahmar M and Wagner AJ},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-0509},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0509}
}

RIS

TY  - JOUR
TI  - Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.
AU  - Schöffski P
AU  - Sanfilippo R
AU  - Martín-Broto J
AU  - Kawai A
AU  - Desai J
AU  - LoRusso P
AU  - Maki RG
AU  - Jones RL
AU  - Blay JY
AU  - Smrke A
AU  - Abdul Razak A
AU  - Italiano A
AU  - Sebio A
AU  - Bahleda R
AU  - Lee YC
AU  - van der Graaf WTA
AU  - Zhang X
AU  - Biyukov T
AU  - Teufel M
AU  - Fu E
AU  - Lahmar M
AU  - Wagner AJ
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-0509
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0509
ER  -

APA

P, S., R, S., J, M., A, K., J, D., P, L., RG, M., RL, J., JY, B., A, S., A, A. R., A, I., A, S., R, B., YC, L., WTA, V. D. G., X, Z., T, B., M, T., E, F., M, L., & AJ, W. (2026). Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0509

Source records

pubmed · retrieved 2026-09-27T12:01:04.262Z
europe-pmc · retrieved 2026-09-27T12:01:04.280Z